Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 8,612 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Disorder Clear all
Completed No phase listed Observational

Biomarkers of Intra-amniotic Infection in Women With Preterm Premature Ruptured Amniotic Membranes

NCT00701350
View directory record Official record
Conditions
Intra-amniotic Infection, Preterm Birth
Interventions
Not listed
Lead sponsor
ProteoGenix, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Phoenix, Arizona • Tucson, Arizona • San Jose, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2010 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

NCT00054860
View directory record Official record
Conditions
HIV Infections
Interventions
EP HIV-1090
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 23, 2026, 1:41 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Apple Respiratory Study

NCT04912180
View directory record Official record
Conditions
Acute Respiratory Infection, Coronavirus Infection, Influenza
Interventions
Not listed
Lead sponsor
Apple Inc.
Industry
Eligibility
22 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 23, 2026, 1:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Atlas Genetics io® CTNG System

NCT03071510
View directory record Official record
Conditions
Chlamydia Trachomatis, Gonorrhea
Interventions
Atlas Genetics io® system
Device
Lead sponsor
Binx Health Limited
Industry
Eligibility
14 Years and older
Enrollment
7,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-323 in Healthy Subjects

NCT05587478
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-323, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional

Handheld Computers to Improve Adherence to Anti-HIV Drug Regimens

NCT00053443
View directory record Official record
Conditions
HIV Infections
Interventions
Medication Reminder System/Adherence Tracker
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Immune Defense Protein Impact On Respiratory Immune Outcomes

NCT07431840
View directory record Official record
Conditions
Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions
Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo
Dietary Supplement
Lead sponsor
Quantec Ltd
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting No phase listed Observational

Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence

NCT05172089
View directory record Official record
Conditions
Chronic Wounds, Biofilm Infection, Trans-epidermal Water Loss (TEWL), Diabetic Foot, Diabetic Foot Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Tucson, Arizona • Cranberry Township, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
25
States / cities
Bakersfield, California • Pasadena, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional

Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC

NCT00001040
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Zidovudine, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 4 Interventional

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

NCT00575224
View directory record Official record
Conditions
Chronic Hepatitis C, Asian Americans, Novel Genotypes, Treatment
Interventions
Pegylated interferon and ribavirin
Drug
Lead sponsor
Pacific Health Foundation
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
San Diego, California • San Jose, California • Westminster, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Oct 23, 2026, 1:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)

NCT05765396
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection, COVID-19 ARDS, Corona Virus Infection, Influenza, RSV Infection
Interventions
imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 1:41 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females

NCT00856596
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot, Foot Fungus, Ringworm
Interventions
Sertaconazole nitrate cream 2%
Drug
Lead sponsor
Jamaica Hospital Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

NCT00000762
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
33
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Not applicable Interventional

Repeat Sexually Transmitted Infection (STI) Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk

NCT01510262
View directory record Official record
Conditions
Sexually Transmitted Infection, HIV
Interventions
Tailored Socio-Contextual Intervention, Standard of Care
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection

NCT06139224
View directory record Official record
Conditions
Alcohol Use Disorder, Human Immunodeficiency Virus
Interventions
4 week prebiotic consumption, 4 week placebo consumption
Dietary Supplement · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting Phase 4 Interventional

Implementing Low-Barrier HCV Treatment in a Jail Setting

NCT06953479
View directory record Official record
Conditions
HEPATITIS C (HCV), Incarceration, Injection Drug Use, Implementation Science
Interventions
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker
Drug · Other
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cranston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

NCT06039579
View directory record Official record
Conditions
HIV Infections
Interventions
VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo, Antiretroviral therapy
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Bakersfield, California • DeLand, Florida • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 4 Interventional Results available

Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C

NCT03365635
View directory record Official record
Conditions
Hepatitis C, Hemodialysis, Nosocomial Infection
Interventions
Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 4 Interventional Results available

Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT00362297
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir, valacyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Not applicable Interventional

A Study of Decreased Mental Function Associated With HIV

NCT00027040
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Selegiline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Not applicable Interventional

Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients

NCT00002174
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women

NCT02010593
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Dapivirine Vaginal Ring, Placebo Vaginal Ring
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

NCT00646958
View directory record Official record
Conditions
Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections, Abscess
Interventions
Radezolid, Linezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Montgomery, Alabama • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 23, 2026, 1:41 AM EDT